Literature DB >> 21354831

Intravenous lacosamide--an effective add-on treatment of refractory status epilepticus.

Johannes Michael Albers1, Gabriel Möddel, Ralf Dittrich, Corinna Steidl, Sonja Suntrup, Erich Bernd Ringelstein, Rainer Dziewas.   

Abstract

Status epilepticus (SE) is a frequent neurological emergency requiring immediate treatment. Therapy usually requires intravenous anticonvulsive medication. Lacosamide is a novel anticonvulsant drug that is available as infusion solution. We describe seven patients with focal SE who were treated with intravenous Lacosamide. All patients in our case series were unsuccessfully treated with other antiepileptic drugs before Lacosamide i.v. was added. In all cases, SE was terminated within 24 h after Lacosamide. There were no serious side effects or adverse events attributable to Lacosamide i.v. Our data suggest that Lacosamide might be an effective add-on treatment, if standard drugs fail or are unsuitable.
Copyright © 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21354831     DOI: 10.1016/j.seizure.2011.01.017

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  10 in total

1.  Usefulness of intravenous lacosamide in status epilepticus.

Authors:  Estevo Santamarina; Manuel Toledo; Maria Sueiras; Miquel Raspall; Nadim Ailouti; Elena Lainez; Isabel Porta; R De Gracia; Manuel Quintana; Javier Alvarez-Sabín; Xavier Salas Puig Xavier Salas Puig
Journal:  J Neurol       Date:  2013-12       Impact factor: 4.849

Review 2.  Novel medications for epilepsy.

Authors:  Cinzia Fattore; Emilio Perucca
Journal:  Drugs       Date:  2011-11-12       Impact factor: 9.546

3.  Safety and efficacy of lacosamide in the intensive care unit.

Authors:  Sunil Cherry; Lilith Judd; Juan Carlos Muniz; Hoda Elzawahry; Suzette LaRoche
Journal:  Neurocrit Care       Date:  2012-04       Impact factor: 3.210

Review 4.  The efficacy of lacosamide as monotherapy and adjunctive therapy in focal epilepsy and its use in status epilepticus: clinical trial evidence and experience.

Authors:  Sebastian Bauer; Laurent M Willems; Esther Paule; Christine Petschow; Johann Philipp Zöllner; Felix Rosenow; Adam Strzelczyk
Journal:  Ther Adv Neurol Disord       Date:  2016-11-29       Impact factor: 6.570

5.  Guidelines for the evaluation and management of status epilepticus.

Authors:  Gretchen M Brophy; Rodney Bell; Jan Claassen; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Suzette M Laroche; James J Riviello; Lori Shutter; Michael R Sperling; David M Treiman; Paul M Vespa
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

Review 6.  Nonconvulsive status epilepticus in adults - insights into the invisible.

Authors:  Raoul Sutter; Saskia Semmlack; Peter W Kaplan
Journal:  Nat Rev Neurol       Date:  2016-04-11       Impact factor: 42.937

7.  Intravenous lacosamide in refractory seizure clusters and status epilepticus: comparison of 200 and 400 mg loading doses.

Authors:  Benjamin Legros; Chantal Depondt; Marcel Levy-Nogueira; Noémie Ligot; Nicolas Mavroudakis; Gilles Naeije; Nicolas Gaspard
Journal:  Neurocrit Care       Date:  2014-06       Impact factor: 3.210

Review 8.  Intravenous and Intramuscular Formulations of Antiseizure Drugs in the Treatment of Epilepsy.

Authors:  Sima I Patel; Angela K Birnbaum; James C Cloyd; Ilo E Leppik
Journal:  CNS Drugs       Date:  2015-12       Impact factor: 5.749

9.  Practice variations in the management of status epilepticus.

Authors:  Aaron M Cook; Amber Castle; Amy Green; Christine Lesch; Christopher Morrison; Denise Rhoney; Dennis Parker; Eljim Tesoro; Gretchen Brophy; Haley Goodwin; Jane Gokun; Jason Makii; Karen McAllen; Kathleen Bledsoe; Kiranpal Sangha; Kyle Weant; Norah Liang; Teresa Murphy-Human
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

10.  Refractory status epilepticus.

Authors:  Sanjay P Singh; Shubhi Agarwal; M Faulkner
Journal:  Ann Indian Acad Neurol       Date:  2014-03       Impact factor: 1.383

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.